About: Radiolabeled antiviral drugs and antibodies as virus-specific imaging probes

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Radiolabeled antiviral drugs and antibodies as virus-specific imaging probes Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Radiolabeled antiviral drugs and antibodies as virus-specific imaging probes
Creator	Bray, Mike Jagoda, Elaine Mollura, Daniel De Kok-Mercado, Fabian Mascio, Michele
topic	covid:04cc401cd690845724a7b04a11fcb11f2e70c96c#this
Source	Elsevier; Medline; PMC
abstract	Abstract A number of small-molecule drugs inhibit viral replication by binding directly to virion structural proteins or to the active site of a viral enzyme, or are chemically modified by a viral enzyme before inhibiting a downstream process. Similarly, antibodies used to prevent or treat viral infections attach to epitopes on virions or on viral proteins expressed on the surface of infected cells. Such drugs and antibodies can therefore be thought of as probes for the detection of viral infections, suggesting that they might be used as radiolabeled tracers to visualize sites of viral replication by single-photon emission computed tomography (SPECT) or positron emission tomography (PET) imaging. A current example of this approach is the PET imaging of herpes simplex virus infections, in which the viral thymidine kinase phosphorylates radiolabeled thymidine analogues, trapping them within infected cells. One of many possible future applications might be the use of a radiolabeled hepatitis C protease inhibitor to image infection in animals or humans and provide a quantitative measure of viral burden. This article reviews the basic features of radionuclide imaging and the characteristics of ideal tracer molecules, and discusses how antiviral drugs and antibodies could be evaluated for their suitability as virus-specific imaging probes. The use of labeled drugs as low-dose tracers would provide an alternative application for compounds that have failed to advance to clinical use because of insufficient in vivo potency, an unsuitable pharmacokinetic profile or hepato- or nephrotoxicity.
has issue date	2010-11-30(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2010.08.005
bibo:pmid	20709111
has license	els-covid
sha1sum (hex)	04cc401cd690845724a7b04a11fcb11f2e70c96c
schema:url	https://doi.org/10.1016/j.antiviral.2010.08.005
resource representing a document's title	Radiolabeled antiviral drugs and antibodies as virus-specific imaging probes
has PubMed Central identifier	PMC7125728
has PubMed identifier	20709111
schema:publication	Antiviral Research
resource representing a document's body	covid:04cc401cd690845724a7b04a11fcb11f2e70c96c#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/04cc401cd690845724a7b04a11fcb11f2e70c96c
is schema:about of	named entity 'pharmacokinetic' named entity 'surface' named entity 'PET' named entity 'viral replication' named entity 'basic' named entity 'inhibit' named entity 'viral infections' named entity 'thymidine' named entity 'modified' named entity 'enzyme' named entity 'IMAGE' named entity 'ALTERNATIVE' named entity 'TREAT' named entity 'USE OF' named entity 'PROVIDE' named entity 'INFECTED' named entity 'THEIR' named entity 'INHIBITING' named entity 'SMALL' named entity 'DIRECTLY' named entity 'AS VIRUS' named entity 'ARTICLE' named entity 'VIRAL REPLICATION' named entity 'MIGHT BE' named entity 'STRUCTURAL PROTEINS' named entity 'CLINICAL' named entity 'TRAPPING' named entity 'REVIEWS' named entity 'INFECTIONS' named entity 'MOLECULE' named entity 'POSITRON EMISSION TOMOGRAPHY' named entity 'NEPHROTOXICITY' named entity 'FEATURES' named entity 'VIRAL BURDEN' named entity 'TRACERS' named entity 'ONE OF' named entity 'HUMANS' named entity 'EXAMPLE' named entity 'PROCESS' named entity 'ADVANCE' named entity 'DRUGS' named entity 'HAVE' named entity 'VISUALIZE' named entity 'QUANTITATIVE' named entity 'CELLS' named entity 'FAILED' named entity 'MODIFIED BY' named entity 'ATTACH' named entity 'PHARMACOKINETIC PROFILE' named entity 'INSUFFICIENT' named entity 'RADIONUCLIDE IMAGING' named entity 'ACTIVE SITE' named entity 'BINDING' named entity 'SURFACE' named entity 'APPLICATION' named entity 'EVALUATED' named entity 'VIRIONS' named entity 'CHARACTERISTICS' named entity 'IDEAL' named entity 'THYMIDINE KINASE' named entity 'PET IMAGING' named entity 'DETECTION' named entity 'HERPES SIMPLEX VIRUS' named entity 'FUTURE' named entity 'ANTIBODIES' named entity 'PROBES' named entity 'TRACER' named entity 'A CURRENT' named entity 'ANTIVIRAL DRUGS' named entity 'NUMBER OF' named entity 'USED' named entity 'APPROACH' named entity 'MOLECULES' named entity 'LOW-DOSE' named entity 'THOUGHT'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software